Petersen, P.C. et al. 2021. A randomized phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma. Acta Oncologica. 60, 7 (Jul. 2021), 948–953. DOI:https://doi.org/10.1080/0284186X.2021.1928281.